首页> 外文期刊>Drug metabolism and drug interactions >Competition between COX-2 inhibitors and some other drugs for binding sites on human serum albumin.
【24h】

Competition between COX-2 inhibitors and some other drugs for binding sites on human serum albumin.

机译:COX-2抑制剂与其他药物在人血清白蛋白结合位点上的竞争。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Competitive binding of six COX-2 inhibitors (celecoxib, valdecoxib, etoricoxib, parecoxib sodium, meloxicam and nimesulide) in the presence of three categories of drugs: an antidiabetic (gliclazide), antipsychotic (chlorpromazine) and antibiotic (ceftriaxone sodium) were studied by fluorescence spectroscopy. Data are expressed in terms of the percentage of drug bound in the absence and presence of competing drug and change in the percentage of free drug due to competitive binding. The results are discussed in terms of three cases: decrease in the binding of the parent drug; increase in binding; and no effect by the presence of the competing drug. The relative binding affinity of the parent drug and the displacing compound for human serum albumin (HSA) is not the only factor involved in the competitive mechanism. Binding behaviour of individual drugs was analysed, and explanations for different cases based on the competitive displacement, non-competitive interference, conformational changes in the HSA molecule, and independent binding are presented.
机译:通过三种药物:抗糖尿病药(格列齐特),抗精神病药(氯丙嗪)和抗生素(头孢曲松钠)对六种COX-2抑制剂(塞来昔布,伐地昔布,依托昔布,帕瑞昔布钠,美洛昔康和尼美舒利)的竞争结合进行了研究。荧光光谱。数据表示为在不存在和存在竞争药物的情况下结合药物的百分比,以及由于竞争性结合而导致的游离药物百分比的变化。从以下三种情况讨论了结果:母体药物结合力降低;增加约束力;并且不会因竞争药物的存在而产生影响。母体药物和置换化合物对人血清白蛋白(HSA)的相对结合亲和力不是参与竞争机制的唯一因素。分析了单个药物的结合行为,并基于竞争性位移,非竞争性干扰,HSA分子的构象变化和独立结合对不同情况进行了解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号